<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590407</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-2200-101</org_study_id>
    <nct_id>NCT01590407</nct_id>
  </id_info>
  <brief_title>First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002200 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alios Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alios Biopharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, 3-part study will assess the safety,&#xD;
      tolerability, and pharmacokinetics of orally administered ALS-002200 in healthy volunteers&#xD;
      (HV) and subjects with chronic hepatitis C (CHC) genotype 1 infection.&#xD;
&#xD;
      Part 1 will assess single ascending dosing pharmacokinetics and safety in HV. Part 2 will&#xD;
      assess food effects on pharmacokinetics in HV. Part 3 will assess multiple ascending dosing&#xD;
      pharmacokinetics and safety in subjects with CHC genotype 1 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2011</start_date>
  <completion_date type="Actual">February 28, 2013</completion_date>
  <primary_completion_date type="Actual">February 28, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>up to Day 31</time_frame>
    <description>data points measured include patient reported adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 240 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 240 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV ribonucleic acid (RNA) viral load reduction</measure>
    <time_frame>Baseline to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino Acid Changes in HCV polymerase NS5b</measure>
    <time_frame>Baseline up to Month 6</time_frame>
    <description>Comparison of baseline with on-treatment or post-treatment Hepatitis C virus (HCV) NS5B RNA sequence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>ALS-002200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALS-002200</intervention_name>
    <description>ALS-002200</description>
    <arm_group_label>ALS-002200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided written consent.&#xD;
&#xD;
          -  In the investigator's opinion, the subject is able to understand and comply with&#xD;
             protocol requirements, instructions, and protocol stated restrictions and is likely to&#xD;
             complete the study as planned.&#xD;
&#xD;
          -  Subject is in good health as deemed by the investigator.&#xD;
&#xD;
          -  Creatinine clearance of greater than 50 mL/min (Cockcroft-Gault)&#xD;
&#xD;
          -  Male or female, 18-55 years of age for HV and 18-65 years of age for subjects with&#xD;
             CHC.&#xD;
&#xD;
          -  Body mass index (BMI) 18-32 kg/m2 inclusive for HV and 18-36 kg/m2 for subjects with&#xD;
             CHC, minimum weight 50 kg in both populations.&#xD;
&#xD;
          -  A female is eligible to participate in this study if she is of non childbearing&#xD;
             potential.&#xD;
&#xD;
          -  If male, subject is surgically sterile or practicing specific forms of birth control.&#xD;
&#xD;
        Additional inclusion criteria for subjects with CHC genotype 1 infection:&#xD;
&#xD;
          -  Positive HCV antibody and a positive HCV RNA at screening.&#xD;
&#xD;
          -  Documentation of CHC infection for greater than 6 months at screening&#xD;
&#xD;
          -  CHC genotype 1 infection at screening&#xD;
&#xD;
          -  HCV RNA viral load ≥ 105 and ≤108 IU/mL using a sensitive quantitative assay.&#xD;
&#xD;
          -  Liver biopsy within two years or Fibroscan evaluation within 6 months prior to&#xD;
             screening that clearly excludes cirrhosis. Fibroscan liver stiffness score must be &lt;&#xD;
             12 kPa.&#xD;
&#xD;
          -  Absence of hepatocellular carcinoma as indicated by an ultrasound scan conducted&#xD;
             during screening&#xD;
&#xD;
          -  No prior treatment for CHC&#xD;
&#xD;
          -  Absence of history of clinical hepatic decompensation.&#xD;
&#xD;
          -  Laboratory values include:&#xD;
&#xD;
               -  Prothrombin time &lt; 1.5x ULN&#xD;
&#xD;
               -  Platelets &gt; 120,000/mm3&#xD;
&#xD;
               -  Albumin &gt; 3.5 g/dL, bilirubin &lt; 1.5 mg/dL at screening (subjects with documented&#xD;
                  Gilbert's disease allowed).&#xD;
&#xD;
               -  Serum alanine aminotransferase (ALT) concentration &lt; 5 x ULN&#xD;
&#xD;
               -  Alpha Fetoprotein (AFP) concentrations ≤ ULN. If AFP is ≥ ULN, absence of a&#xD;
                  hepatic mass must be demonstrated by ultrasound within the screening period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant cardiovascular, respiratory, renal, gastrointestinal,&#xD;
             hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric&#xD;
             disorder.&#xD;
&#xD;
          -  Positive test for HAV IgM, HBsAg, HCV Ab (HV only), or HIV Ab.&#xD;
&#xD;
          -  Abnormal screening laboratory results that are considered clinically significant by&#xD;
             the investigator.&#xD;
&#xD;
          -  Drug allergy such as, but not limited to, sulfonamides and penicillins, including&#xD;
             those experienced in previous trials with experimental drugs.&#xD;
&#xD;
          -  Participation in an investigational drug trial or having received an investigational&#xD;
             vaccine within 30 days or 5 half lives (whichever is longer) prior to study&#xD;
             medication.&#xD;
&#xD;
          -  Clinically significant blood loss or elective blood donation of significant volume.&#xD;
&#xD;
          -  For healthy subjects, history of regular use of tobacco.&#xD;
&#xD;
          -  The subject has a positive pre-study drug screen.&#xD;
&#xD;
          -  Laboratory abnormalities including:&#xD;
&#xD;
               -  Thyroid Stimulating Hormone (TSH) &gt; ULN&#xD;
&#xD;
               -  Hematocrit &lt; 34 %&#xD;
&#xD;
               -  White blood cell counts &lt; 3,500/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Rennes</city>
        <state>Brittany</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arensia</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arensia</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

